{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:34:04Z","timestamp":1793363644401,"version":"4.5.0"},"reference-count":21,"publisher":"The Journal of Rheumatology","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2026,7,15]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the long-term safety and efficacy of dazukibart, a novel antiinterferon \u03b2 monoclonal antibody, in adults with moderate-to-severe dermatomyositis (DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants from 2 cohorts of DM (skin-predominant [SP] and muscle-predominant [MP]) completing a 24-week phase II, double-blind study, were enrolled into a 52-week phase IIb, open-label extension (OLE) study, with a 16-week follow-up post treatment (combined study duration: 92 weeks). The pooled skin analysis set included all SP and MP DM participants with baseline Cutaneous Dermatomyositis Disease Area and Severity Index\u2013Activity (CDASI-A) scores \u2265 14. The primary endpoint was incidence of treatment-emergent adverse events (TEAEs) from week 24 through week 92. Key secondary endpoints were change in CDASI-A and Total Improvement Score (TIS) from week 0 through week 92.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants who received \u2265 1 dose of dazukibart (600 mg) during the OLE study (comprising 9, 15, and 16 participants from the SP cohort, MP cohort, and pooled skin analysis set, respectively) were analyzed (median age 49.5 years, 83% female, 96% White). TEAEs were mild (55%), moderate (38%), or severe (7%), with no treatment-related serious AEs or treatment discontinuations. At week 76, CDASI-A scores improved, with a median change from baseline of \u221224.0 (range \u221233 to \u221212), \u22129.0 (range \u221232 to 1), and \u221223.5 (range \u221233 to \u221212) for participants from the SP cohort, MP cohort, and pooled skin analysis set, respectively. In the MP cohort, TIS (median 65.0, range 2.5-95.0) and associated core set measures, including patient-reported outcomes, improved at week 76. Overall, the observed improvements in outcomes, as indicated by the slight reduction in outcome measures, persisted during the 16-week posttreatment follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The safety and efficacy profiles of dazukibart observed at 24 weeks were sustained through 92 weeks. (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      :\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03181893\">NCT03181893<\/jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05192200\">NCT05192200<\/jats:ext-link>\n                      )\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2026-0146","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T12:25:15Z","timestamp":1785587115000},"page":"1125-1134","source":"Crossref","is-referenced-by-count":1,"title":["Long-Term Safety and Efficacy of Dazukibart in Dermatomyositis: Combined Phase II Results From Double-Blind and Open-Label Extension Studies"],"prefix":"10.3899","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-7115","authenticated-orcid":false,"given":"Ruth Ann","family":"Vleugels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4869-3240","authenticated-orcid":false,"given":"Elena","family":"Peeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-8038","authenticated-orcid":false,"given":"Rohit","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5763-5603","authenticated-orcid":false,"given":"Myron","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0567-1949","authenticated-orcid":false,"given":"Abigail","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Mangialardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7951-3674","authenticated-orcid":false,"given":"David","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"key":"2026100422250787000_53.10.1125.1","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/1346-8138.17170","article-title":"Novel therapeutic targets in dermatomyositis","volume":"51","author":"Bax","year":"2024","journal-title":"J Dermatol"},{"key":"2026100422250787000_53.10.1125.2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/ITT.S381472","article-title":"Dermatomyositis: practical guidance and unmet needs","volume":"13","author":"Cassard","year":"2024","journal-title":"ImmunoTargets Ther"},{"key":"2026100422250787000_53.10.1125.3","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/S2665-9913(23)00322-3","article-title":"Idiopathic inflammatory myopathies: current insights and future frontiers","volume":"6","author":"Connolly","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2026100422250787000_53.10.1125.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.10.016"},{"key":"2026100422250787000_53.10.1125.5","doi-asserted-by":"crossref","first-page":"e944564","DOI":"10.12659\/MSM.944564","article-title":"Pharmacological strategies in dermatomyositis: current treatments and future directions","volume":"30","author":"Guo","year":"2024","journal-title":"Med Sci Monit"},{"key":"2026100422250787000_53.10.1125.6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s13311-015-0394-2","article-title":"Immunotherapies for immune-mediated myopathies: a current perspective","volume":"13","author":"Needham","year":"2016","journal-title":"Neurotherapeutics"},{"key":"2026100422250787000_53.10.1125.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117912"},{"key":"2026100422250787000_53.10.1125.8","first-page":"52","article-title":"Combination therapy of prednisone, azathioprine, and hydroxychloroquine in patient with dermatomyositis","volume":"3","author":"Swanenghyun","year":"2024","journal-title":"AJHR"},{"key":"2026100422250787000_53.10.1125.9","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s40674-021-00182-1","article-title":"Inhibiting interferon pathways in dermatomyositis: rationale and preliminary evidence","volume":"7","author":"Casal-Dominguez","year":"2021","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"2026100422250787000_53.10.1125.10","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/hxin6o"},{"key":"2026100422250787000_53.10.1125.11","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12955"},{"key":"2026100422250787000_53.10.1125.12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/cpdd.887","article-title":"Safety, tolerability, and pharmacokinetics of PF-06823859, an anti-interferon beta monoclonal antibody: a randomized, phase I, single- and multiple-ascending-dose study","volume":"10","author":"Neelakantan","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026100422250787000_53.10.1125.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02071-3"},{"key":"2026100422250787000_53.10.1125.14","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20532"},{"key":"2026100422250787000_53.10.1125.15","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/art.40064","article-title":"American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"69","author":"Aggarwal","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026100422250787000_53.10.1125.16","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","article-title":"American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"76","author":"Aggarwal","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026100422250787000_53.10.1125.17","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13915"},{"key":"2026100422250787000_53.10.1125.18","doi-asserted-by":"crossref","first-page":"100311","DOI":"10.1016\/j.xjidi.2024.100311","article-title":"Long-term safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: follow-up data from a 3-year open-label extension study","volume":"5","author":"Stone","year":"2025","journal-title":"JID Innov"},{"key":"2026100422250787000_53.10.1125.19","first-page":"4","article-title":"Optimization of the diagnostic capacity of traditional biomarkers in muscle damage and its use in the diagnosis of dermatomyositis and polymyositis","volume":"35","author":"Asis","year":"2024","journal-title":"EJIFCC"},{"key":"2026100422250787000_53.10.1125.20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.21037\/atm-25-44","article-title":"Dazukibart for dermatomyositis: expanding the therapeutic arsenal","volume":"13","author":"Pinal-Fernandez","year":"2025","journal-title":"Ann Transl Med"},{"key":"2026100422250787000_53.10.1125.21","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.ard.2026.02.018","article-title":"Inhibition of the type I interferon receptor pathway protects against muscle weakness induced by dermatomyositis serum","volume":"85","author":"Kaewin","year":"2026","journal-title":"Ann Rheum Dis"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2026-0146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:25:29Z","timestamp":1791177929000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2026-0146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":21,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,1]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.3899\/jrheum.2026-0146"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2026-0146","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}